Results 51 to 60 of about 21,275,692 (207)

Chronic obstructive pulmonary disease: a complex comorbidity of lung cancer [PDF]

, 2011
Chronic obstructive pulmonary disease (COPD) is a major burden throughout the world. It is associated with a significantly increased incidence of lung cancer and may influence treatment options and outcome.
Derek Grose MRCP, FRCR, Robert Milroy, Grose, Derek, Milroy, Robert   +3 more
core   +1 more source

Blueprint Of Services For Lung Cancer [PDF]

, 1995
Primary lung cancer is the commonest malignant disease in the developed world, and is the most prevalent form of cancer among men over 65 years. It continues to rise in those aged over 75 years. Mortality from lung cancer is increasing in women.
Doyle, Yvonne G.
core  

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer [PDF]

, 2001
BACKGROUND: The incidence of lung cancer is declining following a drop in smoking rates, but it is still the leading cause of death from cancer in England and Wales, with about 30,000 deaths a year.
A. Clegg, N. Waugh, D. A. Scott, M. Sidhu, Waugh, N, Clegg, A. J., Scott, David A., Waugh, Norman, Clegg, A, Hewitson, P., Hewitson, P, Scott, D A, Sidhu, M, Sidhu, M. K., P. Hewitson   +14 more
core   +1 more source

Synthetic circRNA therapeutics: innovations, strategies, and future horizons

MedComm
Small molecule drugs are increasingly emerging as innovative and effective treatments for various diseases, with mRNA therapeutics being a notable representative.
Jingsheng Cai, Zonghao Qiu, William Chi‐Shing Cho, Zheng Liu, Shaoyi Chen, Haoran Li, Kezhong Chen, Yun Li, Chijian Zuo, Mantang Qiu   +9 more
doaj   +1 more source

Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer [PDF]

, 2010
Lung cancer is the leading cause of cancer deaths, because ~84% of cases are diagnosed at an advanced stage. Worldwide in 2008, ~1.5 million people were diagnosed and ~1.3 million died – a survival rate unchanged since 1960.
Alex Stewart, Stewart, A, Joel L Weissfeld, William L. Bigbee, Mehan Mike, Rom, William N, Stewart, Alex, Gold Larry, Miller, YE, Edward N. Brody, William N Rom, Weissfeld, JL, Harvey I Pass, Siegfried, JM, Pass Harvey I., Stephen Williams, Siegfried, Jill M, Walker, Jeffrey J, Walker Jeffrey J., Bigbee, William L, William L Bigbee, Pass, Harvey I, Rachel M Ostroff, Ostroff, RM, Weissfeld Joel L., Gold, Larry, Bigbee William L., York E. Miller, Zichi Dom, York E Miller, Weissfeld, Joel L, William N. Rom, Gold, L, Franklin Wilbur, Joel L. Weissfeld, Edward N Brody, Franklin, Wilbur, Williams Stephen, Rom, WN, Miller York E., Jeffrey J Walker, Franklin, W, Zichi, D, Mehan, M, Miller, York E, Harvey I. Pass, Brody, EN, Bigbee, WL, Ostroff, Rachel M, Walker, JJ, Rom William N., Williams, Stephen, Dom Zichi, Stewart Alex, Pass, HI, Mehan, Mike, Wilbur Franklin, Brody Edward N., Siegfried Jill M., Mike Mehan, Williams, S, Zichi, Dom, Jill M Siegfried, Rachel M. Ostroff, Ostroff Rachel M., Jeffrey J. Walker, Jill M. Siegfried, Larry Gold, Brody, Edward N   +68 more
core   +1 more source

Deep sequence analysis of non-small cell lung cancer: Integrated analysis of gene expression, alternative splicing, and single nucleotide variations in lung adenocarcinomas with and without oncogenic KRAS mutations [PDF]

, 2012
KRAS mutations are highly prevalent in non-small cell lung cancer (NSCLC), and tumors harboring these mutations tend to be aggressive and resistant to chemotherapy.
David Rossell, Xiaojia eTang, Tang, Xiaojia, Hossain, Asif, Rossell, David, Asha Nair, Jean-Pierre Kocher, Chai, High-Seng, Michael P. Walsh, Asif eHossain, Yan W. Asmann, Baker, Tiffany R., Edith A. Perez, Kalari, Krishna R., Necela, Brian M., Alan P. Fields, High Seng eChai, Xiaojia Tang, Alan P Fields, Leontovich, Alexey A., Carr, Jennifer, Thompson, E. Aubrey, Saurabh Baheti, Kocher, Jean-Pierre, Tiffany R Baker, Younkin, Curtis S., Walsh, Michael P., E. Aubrey Thompson, Jennifer M. Kachergus, Jennifer M Kachergus, Jennifer M Carr, Fields, Alan P., Asmann, Yan W., Krishna R. Kalari, E. Aubrey eThompson, Kachergus, Jennifer M., Steven N Hart, Krishna R Kalari, Jennifer M. Carr, David eRossell, Saurabh eBaheti, Steven N. Hart, Curtis S. Younkin, Zhifu eSun, Edith A Perez, Tiffany Baker, Brian M Necela, Alexey A. Leontovich, Nair, Asha, Perez, Edith A., Sun, Zhifu, Reisman, David N., Jean-Pierre eKocher, Asha eNair, Hart, Steven N., Yan W Asmann, Zhifu Sun, Michael eWalsh, Baheti, Saurabh, David N Reisman, Brian M. Necela, High-Seng Chai, David N. Reisman, Alexey A Leontovich, Asif Hossain, Curtis S Younkin   +65 more
core   +1 more source

Validation for revision of the stage IIIA(T1N2) in the forthcoming ninth edition of the TNM classification for lung cancer

BMC Cancer
Objectives The 9th edition of the lung cancer tumor-node-metastasis (TNM) staging system downgrades certain non-small cell lung cancer (NSCLC) patients from stage IIIA (T1N2) to IIB(T1N2a).
Tong Wu, Jingsheng Cai, Yun Li, Rongjing Xie, Kezhong Chen   +4 more
doaj   +1 more source

External validation of pathological T adjustments in the ninth edition of the pleural mesothelioma tumor-node-metastasis classification

Frontiers in Oncology
IntroductionIn the ninth edition pleural mesothelioma (PM) pathological (p) T staging, patients with fissural invasion are upgraded from T1 to T2. This study aimed to externally validate this staging modification.MethodsResected pT1/2 PM patients were ...
Zheng Liu, Zheng Liu, Zheng Liu, Zheng Liu, Jingsheng Cai, Jingsheng Cai, Jingsheng Cai, Jingsheng Cai, Yun Li, Yun Li, Wenhan Weng, Wenhan Weng   +11 more
doaj   +1 more source

Long Non-Coding RNA CAR10 Facilitates Non-Small Cell Lung Cancer Cell Migration and Invasion by Modulating the miR-892a/GJB2 Pathway

Cancer Management and Research, 2021
Shanshan Li1 *,* Yize Liu2 *,* Guanzhen Qiu,2 Yinzhou Luo,2 Lan Luan,3 Tiance Xu,4 Yong Wang,2,5 Shuyue Xia1,6 1Respiratory Department, Central Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning, 110024, People’s Republic of China;
Li S, Liu Y, Qiu G, Luo Y, Luan L, Xu T, Wang Y, Xia S   +7 more
doaj  

Analysis of Efficacy and Safety of Neoadjuvant Immunochemotherapy in Patients
with Stage IB-IIIB Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer
Background and objective Neoadjuvant immunochemotherapy has emerged as an indispensable therapeutic modality for non-small cell lung cancer (NSCLC).
Zihao LI, Xin WANG, Yulong WANG, Zhuoer CUI, Xin WANG, Xiao LI, Guanchao JIANG, Xun WANG   +7 more
doaj   +1 more source